If you have been reading about freeze-thaw cycling and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Wills Professor of Physics, University of Bristol. For services to Physics. Professor Henry John Evans. For services to Medical Research. James Stuart Fair, Chairman, Dundee Teaching Hospitals NHS Trust. For services to Health Care. Jonathan Farquharson, lately Legal Commissioner, Charity Commission. Thomas Hugh Francis Farrell, , Pro-Chancellor and Chairman of Council, University of Hull. For services to Higher Education. David Geoffrey Nigel Filkin, Secretary, Association of District Councils. For services to Local Government. Stanley Fishman, President, Cinema Exhibitors' Association. For services to the Film Industry. Frederick Forsyth, Writer. For services to Literature. Michael John Ernest Frye, Chief Executive, B. Elliott plc. For services to Business. Professor Charles Albert Eric Goodhart, Professor of Banking and Finance, London School of Economics. For services to Monetary Economics. Peter James Grant, Chairman, Highlands and Islands Airports Ltd. For services to Industry. Paul Frederick Gribble. For political service. Ewan William Harper. For services to the Church of England. Derek James Harrington, Deputy Chairman and Chief Executive, Port of Felixstowe Ltd., and Director, Hutchison International Port Holdings. For services to the Ports Industry. Peregrine Andrew Morny Cavendish, Marquess of Hartington, lately Senior Steward of the Jockey Club and Chairman, British Horse Racing Board. For services to Horse Racing. David Hewitt. For services to the Community. Pamela Jean Hibbs, , Chief Nurse and Director of Quality Assurance, Royal Hospitals NHS Trust, London.
=== History of claimed benefits === In 1888, an article appeared in Scientific American discussing potential germicidal activity of tobacco smoke providing immunity against yellow fever epidemic of Florida inspiring research in the lab of Vincenzo Tassinari at the Hygienic Institute of the University of Pisa, who explored the antimicrobial activity against pathogens including Bacillus anthracis, Mycobacterium tuberculosis, Bacillus prodigiosus, Staphylococcus aureus, and others. Carbon monoxide is a bioactive component of tobacco smoke that has been explored for its antimicrobial properties against many of these pathogens. On epidemiological grounds, unexpected correlations between smoking and favorable outcomes initially emerged in the context of cardiovascular disease, where they were described as a smoker's paradox (or smoking paradox). The term smoker's paradox was coined in 1995 in relation to reports that smokers appeared to have unexpectedly good short-term outcomes following acute coronary syndrome or stroke. One of the first reports of an apparent smoker's paradox was published in 1968 based on an observation of relatively decreased mortality in smokers one month after experiencing acute myocardial infarction. In the same year, a case–control study first suggested a possible protective role in Parkinson's disease. Historical claims of possible benefits in schizophrenia, whereby smoking was thought to ameliorate cognitive symptoms, are not supported by current evidence.
At the time, "yeast nucleic acid" (RNA) was thought to occur only in plants, while "thymus nucleic acid" (DNA) only in animals. The latter was thought to be a tetramer, with the function of buffering cellular pH. In 1937, William Astbury produced the first X-ray diffraction patterns that showed that DNA had a regular structure. In 1943, Oswald Avery, along with co-workers Colin MacLeod and Maclyn McCarty, identified DNA as the transforming principle, supporting Griffith's suggestion (Avery–MacLeod–McCarty experiment). Erwin Chargaff developed and published observations now known as Chargaff's rules, stating that in DNA from any species of any organism, the amount of guanine should be equal to cytosine and the amount of adenine should be equal to thymine.
==== Philippines ==== The Chinese are being blamed after a cybersecurity company, F-Secure Labs, found a malware, NanHaiShu, which targeted the Philippines Department of Justice. It sent information in an infected machine to a server with a Chinese IP address. The malware which is considered particularly sophisticated in nature was introduced by phishing emails that were designed to look like they were coming from an authentic sources. The information sent is believed to be relating to the South China Sea legal case.
Sources: en.wikipedia.org
Polling indicated that the majority of voters support a ceasefire and American mediation in the Gaza war. According to a YouGov poll in March 2024, 52% of Americans supported stopping weapons shipments to Israel, coming largely from Americans who voted for Biden in 2020 (62% support) and people who did not vote in 2020 (60%). 55% of Americans who voted for Trump in 2020 opposed halting weapons shipments, while 30% supported the measure. Republicans generally supported arms to Israel, while Democrats were divided on the issue. Harris largely continued Biden's approach to the Israeli–Palestinian conflict, although she was seen as more sympathetic to Palestinians than Biden or Trump. During the Gaza war, Harris supported Israel's offensive, saying "the threat Hamas poses to the people of Israel must be eliminated". By March 2024, Harris was increasingly critical of Israel, calling for a ceasefire and two-state solution, and opposing the Rafah offensive, though still supporting the war overall. In the Democratic primaries, the Uncommitted National Movement led a protest campaign against Biden and later Harris over the war, calling for a ceasefire and arms embargo on Israel. It received over 700,000 votes and 36 delegates. Harris engaged with Uncommitted and Arab-American leaders, but refused to change her position. Harris argued for continued weapons shipments to Israel, saying it had a right to defend itself. Uncommitted ultimately encouraged its supporters to vote for Harris, though many were reluctant.
Prominent figures included ethnic Mongol general Ulanhu, who served in high-ranking roles in the Inner Mongolian region and as vice president of China, and Saifuddin Azizi, a Lieutenant General and an ethnic Uyghur who served in the CCP Central Committee. There were a few instances of ethnic distrust within the PLA, with one prominent example being the defection of Margub Iskhakov, an ethnic Muslim Tatar PLA general, to the Soviet Union in the 1960s. However, his defection largely contributed to his disillusion with the failed Great Leap Forward policies, instead of his ethnic background. In modern times, ethnic representation is most visible among junior-ranking officers. Only a few minorities reach the highest-ranking positions.
== Human proteins containing this domain == EEF1E1; EEF1G; GDAP1; GSTA1; GSTA2; GSTA3; GSTA4; GSTA5; GSTM1; GSTM2; GSTM3; GSTM4; GSTM5; GSTO1; GSTP1; GSTT1; GSTT2; GSTZ1; MARS; HPGDS; PTGDS2; PTGES2; VARS;
Sources: en.wikipedia.org
=== Pharmacodynamics === para-Chlorophenethylamine acts primarily as a serotonin-releasing agent with an EC50Tooltip Half maximal effective concentration value of 430 nM for the serotonin transporter, approximately the dose required to induce serotonin syndrome with seizures, tremor, and hyperthermia in mice, is quite low compared to other derivatives (such as ortho-chlorophenethylamine and meta-chlorophenethylamine) In mice with serotonin syndrome induced by para-chlorophenethylamine, the following symptoms were observed: lateral head bobbing, a Straub tail reaction, abduction of the hind limbs, tremors, hyperactivity, mutual pawing with the front paws, salivation, and piloerection. It acts as a full, weak agonist of TAAR with an EC50 value of 2,900 ± 1,000 nM. In vitro, it inhibited the activity of the enzyme phenylethanolamine N-methyltransferase. Para-chlorophenelethylamine stimulated 5-HT receptors.
Mads Krogsgaard Thomsen (born December 27, 1960) is a Danish businessman who is the CEO of the Novo Nordisk Foundation and former executive vice president of research & development (R&D), head of R&D and chief scientific officer at the pharmaceutical company Novo Nordisk.
== Comparison of somatostatin receptor agonists and antagonists in radiolabelling == Agonists of the somatostatin receptor had been long established as an imaging agent, with the first agonist Ga-DOTATOC coming out in 2001, which is based on a radiolabeled somatostatin receptor agonist drug octreotide, and further developments were based on its structure. Agonists share the characteristic of being uptaken into tumor cells, and degraded intracellularly. Antagonists, while not widely absorbed into the tumor cells, can bind to a wider range of receptors as they can bind to the receptors regardless if the receptors are activated or inactivated. They thus are more sensitive to neuroendocrine tumors. Another study noted the antagonists showed lowered internalization into tumors, cleared from the blood quickly, and had a higher binding to tumors, which were noted to be properties benefitting its use over agonists in detecting metastatic tumors. A head-to-head study of the gallium-containing compounds, where the Ga-NODAGA-JR11 antagonist and Ga-DOTATOC agonist are directly compared, showed that Ga-NODAGA-JR11 had a higher hepatic metastatic tumor detection rate and lesion sensitivity than Ga-DOTATOC. Another head-to-head study of lutetium containing compound found the antagonist Lu-DOTA-JR11 bound with the receptors more quickly, had a longer retention time, and unbound more slowly than the Lu-DOTA-TATE agonist.
==== Venus landings ==== In 1970, the Soviet Union's Venera 7 marked the first time a spacecraft was able to return data after landing on another planet. Venera 7 held a resistant thermometer and an aneroid barometer to measure the temperature and atmospheric pressure on the surface, the transmitted data showed 475 C at the surface, and a pressure of 92 bar. In 1975, Venera 9 established an orbit around Venus and successfully returned the first photography of the surface of Venus. Venera 10 landed on Venus and followed with further photography shortly after. NASA initiated the Pioneer Venus project in 1978, successfully deploying four small probes into the Venusian atmosphere on December 9, 1978. The probes confirmed that Venus has little if any magnetic field, and cameras detected lightning in the atmosphere. The last transmissions were received on October 8, 1992, as its decaying orbit no longer permitted communications. The spacecraft burned up the atmosphere soon after, ending a successful 14-year mission that was planned to last only eight months. In 1981, Venera 13 performed a successful soft-landing on Venus and marked the first probe to drill into the surface of another planet and take a sample. Venera 13 also took an audio sample of the Venusian environment, marking another first. Venera 13 returned the first color images of the surface of Venus, revealing an orange-brown flat bedrock surface covered with loose regolith and small flat thin angular rocks. Venera 14, an identical spacecraft to Venera 13, was launched 5 days apart with a similar mission profile.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.